Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

Healthcare Drug Manufacturers - Specialty & Generic
"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

VALEANT PHARMACEUTICALS INTL INC > 2012 VALEANT $56.00 with a B1 rating from Moody
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by johnnywickon Jan 02, 2018 8:11pm
246 Views
Post# 27266560

RE:2012 VALEANT $56.00 with a B1 rating from Moody

RE:2012 VALEANT $56.00 with a B1 rating from Moody
don't be a fool

this company valeant going to be $100.00 again in the near future

debt talk / moody junk rating.. they're meaningless

focus on what's already out of the pipeline and what other new drugs coming out of the pipeline.. never short a stock when their old drugs sales are rebounding and their new drugs sales accelerating..

Valeant easy double from here in 2018
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities